Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Verweij

Showing results (81-90 of 655) with videos related to

Pageof 66
Sort By:
Journal of Medical Ethics|June 29, 2021
Twin pregnancy reduction is not an 'all or nothing' problem: a response to RäsänenDunja Begović, Elizabeth Chloe Romanis, E J Verweij
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1988
Mitomycin CJ den Hartigh, J Verweij, H M Pinedo
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1987
Mitomycin CJ Den Hartigh, J Verweij, H M Pinedo
Trends in Parasitology|December 21, 2010
The impact of genetic diversity in protozoa on molecular diagnosticsC Rune Stensvold, Marianne Lebbad, Jaco J Verweij
Anti-Cancer Drugs|August 1, 1991
5-HT3 receptor antagonists, a new approach in emesis: a review of ondansetron, granisetron and tropisetronC Seynaeve, J Verweij, P H de Mulder
Drugs|January 1, 1996
Emerging drug treatments for solid tumoursJ H Schellens, L C Pronk, J Verweij
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2001
Docetaxel and cisplatin in head and neck cancerP Schöffski, J Wanders, J Verweij, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 20, 2007
Systematic review on the use of systemic anticancer therapy in renal-impaired gynecological cancer patientsF A de Jong, J Verweij, A Sparreboom
Cancer Treatment Reviews|October 13, 1998
The development of combination therapy involving camptothecins: a review of preclinical and early clinical studiesM J de Jonge, A Sparreboom, J Verweij
Nederlands Tijdschrift Voor Geneeskunde|January 5, 2002
[Developments in chemotherapy; cytostatic agents with an increased specificity and other forms of administering cytotoxic antineoplastic agents]F A Eskens, M J de Jonge, J Verweij
Pageof 66

Showing results (81-90 of 655) with videos related to

Sort By:
Pageof 66
Journal of Medical Ethics|June 29, 2021
Twin pregnancy reduction is not an 'all or nothing' problem: a response to RäsänenDunja Begović, Elizabeth Chloe Romanis, E J Verweij
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1988
Mitomycin CJ den Hartigh, J Verweij, H M Pinedo
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1987
Mitomycin CJ Den Hartigh, J Verweij, H M Pinedo
Trends in Parasitology|December 21, 2010
The impact of genetic diversity in protozoa on molecular diagnosticsC Rune Stensvold, Marianne Lebbad, Jaco J Verweij
Anti-Cancer Drugs|August 1, 1991
5-HT3 receptor antagonists, a new approach in emesis: a review of ondansetron, granisetron and tropisetronC Seynaeve, J Verweij, P H de Mulder
Drugs|January 1, 1996
Emerging drug treatments for solid tumoursJ H Schellens, L C Pronk, J Verweij
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2001
Docetaxel and cisplatin in head and neck cancerP Schöffski, J Wanders, J Verweij, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 20, 2007
Systematic review on the use of systemic anticancer therapy in renal-impaired gynecological cancer patientsF A de Jong, J Verweij, A Sparreboom
Cancer Treatment Reviews|October 13, 1998
The development of combination therapy involving camptothecins: a review of preclinical and early clinical studiesM J de Jonge, A Sparreboom, J Verweij
Nederlands Tijdschrift Voor Geneeskunde|January 5, 2002
[Developments in chemotherapy; cytostatic agents with an increased specificity and other forms of administering cytotoxic antineoplastic agents]F A Eskens, M J de Jonge, J Verweij
Pageof 66